ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer Efficacy, Safety, and Survival Predictors

Liu, Qingxing; Kulkarni, Harshad R.; Zhao, Tianzhi; Schuchardt, Christiane; Chen, Xiaoyuan; Zhu, Zhaohui*; Zhang, Jingjing*; Baum, Richard P.*南方医科大学; 中国医学科学院; 中国医学科学院北京协和医院; 1; 5
CLINICAL NUCLEAR MEDICINE2023-3DOI: 10.1097/RLU.0000000000004539
2被引4阅读
引用收藏
分享

摘要

PurposeProgressive metastatic medullary thyroid carcinoma (MTC) is often characterized by rapid disease progression and poor prognosis, with only few therapeutic options available. Peptide receptor radionuclide therapy (PRRT) has demonstrated remarkable success in the management of gastroenteropancreatic neuroendocrine tumors and has also been suggested to treat MTC. However, evidence on its effectiveness and long-term outcome for this indication is still limited. The objective of this study was to assess the safety and efficacy of PRRT in patients with advanced, progressive MTC and to determine survival. Potential predictors of survival were also evaluated.MethodsFrom September 2003 to June 2019, 28 patients (15 men and 13 women; mean age, 49 +/- 14 years) with progressive, somatostatin receptor-positive advanced MTC received PRRT with Lu-177- or Y-90-labeled somatostatin analogs at Zentralklinik Bad Berka, Germany. Toxicity was graded according to Common Terminology Criteria for Adverse Events version 5.0. Treatment response was evaluated according to RECIST (Response Evaluation Criteria in Solid Tumors) 1.1, as well as molecular imaging criteria (European Organisation for Research and Treatment of Cancer). Kaplan-Meier analysis was used to calculate progression-free survival (PFS) and overall survival (OS), defined from the start of PRRT. Univariate and multivariate Cox regression analyses were performed to identify parameters associated with PFS and OS.ResultsSeventy-seven cycles of PRRT were administered (mean cumulative administered activity, 16.0 +/- 7.8 GBq). No acute or long-term grade 3/4 toxicity was recorded with a follow-up of 3 to 140 months, except for 1 patient (4%) who suffered from grade 3 anemia (possibly related to disease progression). According to the RECIST criteria, the disease control rate after 3 to 4 months of PRRT was 56% (partial remission, 12%; stable disease, 44%). The disease control rate (72%) was higher by molecular response evaluation. Median OS and PFS were 63.7 and 10.1 months, respectively. The annual OS rates were 84% at 1 year, 65% at 3 years, 57% at 5 years, and 18% at 10 years. The annual PFS rates were 42% at 1 year, 21% at 2 years, and 13% at 5 years. Patients with bone metastases had poorer OS and PFS than those without metastases (median OS, 58.7 vs 92.3 months [P = 0.035; hazard ratio, 2.7; 95% confidence interval, 0.92-7.84]; median PFS, 8.5 vs 12.8 months [P = 0.592; hazard ratio, 1.2; 95% confidence interval, 0.56-2.76]).ConclusionsPeptide receptor radionuclide therapy was well tolerated and effective in patients with advanced, aggressive MTC. Bone metastasis was an independent adverse prognostic factor for OS.

学科与关键词

关键词
Lu-177Y-90medullary thyroid cancerpeptide receptor radionuclide therapysafetysurvival
相关
加载中…
  • Prognosis of radiotherapy in medullary thyroid carcinoma patients without distant metastasis
    Huang, Shaojun; Zhong, Jiana; Zhang, Zhen; Chen, Rongping; Li, Jitong; Sun, Jia*; Chen, Hong*Translational Cancer Research, 2021, 10(11): 4714-+.被引 1
  • Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors
    Jiang, Yuanyuan; Liu, Qingxing; Wang, Guochang; Sui, Huimin; Wang, Rongxi; Wang, Jiarou; Zhang, Jingjing; Zhu, Zhaohui*; Chen, Xiaoyuan*2022, 12(15): 6437-6445.被引 2
  • Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study
    Zhao, Jingzhu; Chi, Yihebali; Hu, Chuanxiang; Chen, Xiaohong; Ge, Minghua; Zhang, Yuan; Guo, Zhuming; Wang, Jun; Chen, Jie; Zhang, Jiewu; Cheng, Ying; Li, Zhendong; Liu, Hui; Qin, Jianwu; Zhu, Jingqiang; Cheng, Ruochuan; Xu, Zhengang; Li, Dapeng; Tang, Pingzhang; Gao, Ming*; Zheng, Xiangqian*Frontiers in Oncology, 2022, 12: 852032.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
CLINICAL NUCLEAR MEDICINE
发表日期
2023-03
卷期
第 48 卷, 第 3 期
页码
221-227
DOI
10.1097/RLU.0000000000004539
语言
ENGLISH
成果收录
SCIE

作者

  • L

    Liu, Qingxing (第一作者)

    chinese acad med sci · peking union med coll · peking union med coll hosp · southern med univ

  • K

    Kulkarni, Harshad R.

查看全部 8 位作者收起作者
  • Z

    Zhao, Tianzhi

  • S

    Schuchardt, Christiane

  • C

    Chen, Xiaoyuan

  • Z

    Zhu, Zhaohui (通讯)

    chinese acad med sci · peking union med coll · peking union med coll hosp · 1

  • Z

    Zhang, Jingjing (通讯)

    5

  • B

    Baum, Richard P. (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417